Private Equity
Andrea Alms Video: Money In Motion 150 - Gene Therapy Adeno-Associated Virus (AAV)
March 2025 - Private Equity
TRANSCRIPT: Hello, my name is Andrea Alms. I'm a technology investor and financial manager and this is your money in motion. AAV stands for Adeno Associated Virus. Gene therapy is important as it is a leading platform for delivering genes to treat various diseases. Note that this is intended to correct the genetic defect that causes the disease. The first approved gene therapy clinical research in the U.S. corrected a gene defect I took place in September 14th, 1990, at the National Institutes of Health, treating a four year old girl with add a side. These are truly innovative, novel, and remarkable in human history. Examples of RV based gene therapies include like sauna, a gene therapy for a rare form of inherited blindness called LCA.
Glide barrier, a gene therapy for rare metabolic disorder called LP D and hemophilia B. There are AAV based gene therapies developing for treating hemophilia B, which is a rare hereditary bleeding disorder. At VMI, the global market was 5.3 billion in 2023 and estimated to be 14.7 billion by 2030, growing at a compound average growth rate of 15.1%. At I mark, the market size was 1.9 billion in 2023, projected to grow to 75.1 billion by 2034 at a growth rate of 39.9%.
At Market Research Intellect, the market was 5.11 billion in 2023 and expected to reach 25.69 billion in 2031, a growth rate of 14.3%. Averaging the averages, the market was 4.1 billion at 23.1% growth rate. Thank you. This is your money. Your money in motion.